JAMES MCCORMACK: Open Payments
NPI 1487102596 · CONWAY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,087 in 50 payments from 10 companies in 2025. Trend: 2023 $2,179 · 2024 $719 · 2025 $1,087
Food & beverage: $1,087
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $258 |
| Vanda Pharmaceuticals Inc. | 10 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $194 |
| Alkermes, Inc. | 6 | $127 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Lundbeck LLC | 5 | $81 |
| ABBVIE INC. | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: CAPLYTA, REXULTI, FANAPT, ARISTADA, ABILIFY MAINTENA, Auvelity, HETLIOZ, VRAYLAR.
Industry payments across AR — which companies pay providers there.
